Report cover image

United States Insulin Delivery Market Outlook to 2033

Publisher GlobalData
Published Dec 31, 2024
Length 47 Pages
SKU # GBDT19541588

Description

United States Insulin Delivery Market Outlook to 2033

Summary

GlobalData’s “United States Insulin Delivery Market Outlook to 2033” is a comprehensive databook report, covering key market data on the United States Insulin Delivery market. The databook report provides value (USD), volume (units) and average prices (USD) within market segments - Insulin Pens and Insulin Pumps

The United States Insulin Delivery Market report provides key information and data on -
  • Annualized market revenues (USD), volume (units) and average prices (USD) data for each of the market segments. Data is provided from 2018 to 2033.
  • 2023 company share and distribution share data for Insulin Delivery Market.
  • Global corporate-level profiles of key companies operating within the United States Insulin Delivery Market. Based on the availability of data for the particular category and country, information related to pipeline products, news and deals is also available in the report.
Scope

United States Insulin Delivery is segmented as follows -
  • Insulin Pens
  • Insulin Pumps
Reasons to Buy

The United States Insulin Delivery Market report helps you to develop -
  • Business strategies by identifying the key market segments poised for strong growth in the future.
  • Market-entry and market expansion strategies.
  • Design competition strategies by identifying who-stands-where in the market.
  • Develop investment strategies by identifying the key market segments expected to register strong growth in the near future.
  • Understand the key distribution channels and what’s the most preferred mode of product distribution - Identify, understand and capitalize.

Table of Contents

47 Pages
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 What Is This Report About?
2.2 Insulin Delivery Market Segmentation
2.3 Definitions of Markets Covered in the Report
3 Insulin Delivery Market, United States
3.1 Insulin Delivery Market, United States, Revenue ($m), 2018-2033
3.1.1 Insulin Pens Market, United States, Revenue ($m), by Segment, 2018-2033
3.1.2 Insulin Pumps Market, United States, Revenue ($m), by Segment, 2018-2033
3.2 Insulin Delivery Market, United States, Volume (Units), 2018-2033
3.2.1 Insulin Pens Market, United States, Volume (Units), by Segment, 2018-2033
3.2.2 Insulin Pumps Market, United States, Volume (Units), by Segment, 2018-2033
3.3 Insulin Delivery Market, United States, Average Price ($) , 2018-2033
3.4 Insulin Delivery Market, United States, Distribution Share by Revenue ($m), 2023
3.5 Insulin Delivery Market, United States, Company Share by Revenue ($m), 2023
4 Overview of Key Companies in United States, Insulin Delivery Market
4.1 Eli Lilly and Co
4.1.1 Company Overview
4.2 Novo Nordisk AS
4.2.1 Company Overview
4.3 Medtronic Plc
4.3.1 Company Overview
4.4 Sanofi
4.4.1 Company Overview
4.5 Insulet Corp
4.5.1 Company Overview
4.6 Tandem Diabetes Care Inc
4.6.1 Company Overview
5 Insulin Delivery Market Pipeline Products
6 Financial Deals Landscape
6.1 Debt Offerings
6.1.1 Eli Lilly Raises USD750 Million in Public Offering of 4.150% Notes due 2027
6.1.2 Eli Lilly Raises USD1 Billion in Public Offering of 4.2% Notes due 2029
7 Recent Developments
7.1 Corporate Communications
7.1.1 Mar 06, 2024: Tandem Diabetes Care Prices Upsized Private Placement of $275.0 Million of Convertible Senior Notes Due 2029
7.1.2 Mar 04, 2024: Tandem Diabetes Care Announces Proposed Private Placement of Convertible Notes
7.1.3 Mar 04, 2024: Nektar Therapeutics Announces $30 Million Private Placement Financing with TCGX
7.2 Financial Announcements
7.2.1 Nov 07, 2024: Nektar Therapeutics Reports Third Quarter 2024 Financial Results
7.2.2 Oct 31, 2024: MannKind Corporation to Hold 2024 Third Quarter Financial Results Conference Call on November 7, 2024
7.2.3 Oct 16, 2024: Lilly Confirms Date and Conference Call for Third-Quarter 2024 Financial Results Announcement
7.2.4 Oct 10, 2024: BD to Announce its Fiscal 2024 Fourth Quarter and Full Year Financial Results
7.2.5 Sep 26, 2024: Integer Schedules Third Quarter 2024 Earnings Release and Conference Call for October 24, 2024
7.2.6 Jul 03, 2024: BD to Announce Financial Results for its Third Quarter of Fiscal 2024
7.2.7 Jun 04, 2024: Johnson & Johnson to Host Investor Conference Call on Second-Quarter Results
7.2.8 May 01, 2024: MannKind Corporation to Hold 2024 First Quarter Financial Results Conference Call on May 8, 2024
7.2.9 Apr 16, 2024: Lilly Confirms Date and Conference Call for First-Quarter 2024 Financial Results
7.2.10 Apr 03, 2024: Insulet to Announce First Quarter 2024 Financial Results on May 9, 2024
7.2.11 Feb 20, 2024: MannKind Corporation to Hold 2023 Fourth Quarter and Full Year Financial Results Conference Call on February 27, 2024
7.3 Government and Public Interest
7.3.1 Oct 04, 2024: Johnson & Johnson to Participate in the Guggenheim Global Healthcare Conference
7.3.2 Apr 24, 2024: Merus Announces Presentation MCLA-129 at the 2024 ASCO Annual Meeting
7.3.3 Apr 22, 2024: Johnson & Johnson to Participate in the Bernstein’s 40th Annual Strategic Decisions Conference (SDC)
7.3.4 Apr 02, 2024: Johnson & Johnson to Participate in the BofA Securities Health Care Conference
7.3.5 Mar 04, 2024: Biden-Harris Administration Receives Counteroffers from Drug Companies as Part of Ongoing Negotiations to Lower Drug Prices
7.3.6 Feb 14, 2024: Johnson & Johnson to Participate in the Barclays 26th Annual Global Healthcare Conference
7.3.7 Feb 13, 2024: Insulet to Present at The Raymond James & Associates 45th Annual Institutional Investors Conference
7.4 Legal And Regulatory
7.4.1 Aug 14, 2024: Enrollment Completed in Phase 3 Clinical Study of Disitamab Vedotin Combined with PD-1 Inhibitor as First-Line Treatment for Urothelial Carcinoma
7.5 Product News
7.5.1 Mar 06, 2024: embecta-sponsored Educational Symposium and Abstracts at ATTD Highlight Role of Insulin Pumps in the Management of Type 2 Diabetes
8 Appendix
8.1 Research Methodology
8.1.1 Coverage
8.1.2 Secondary Research
8.1.3 Primary Research
8.1.4 Market Modeling and Forecasting
8.1.5 Company Share Analysis
8.1.6 Distribution Share Analysis
8.1.7 Benchmarking
8.2 GlobalData Consulting
8.3 Contact Us
8.4 Disclaimer
List of Tables
Table 1: Insulin Delivery Market, United States, Revenue ($m), USD Constant, 2018-2033
Table 2: Insulin Pens Market, United States, Revenue ($m), USD Constant, 2018-2033
Table 3: Insulin Pumps Market, United States, Revenue ($m), USD Constant, 2018-2033
Table 4: Insulin Delivery Market, United States, Volume (Units), 2018-2033
Table 5: Insulin Pens Market, United States, Volume (Units), 2018-2033
Table 6: Insulin Pumps Market, United States, Volume (Units), 2018-2033
Table 7: Insulin Delivery Market, United States, Average Price ($), 2018-2033
Table 8: Insulin Delivery Market, United States, Distribution Share by Revenue ($m), USD Constant, 2023
Table 9: Insulin Delivery Market, United States, Company Share by Revenue ($m), USD Constant, 2023
Table 10: Insulin Delivery Market Pipeline Products
Table 11: Eli Lilly Raises USD750 Million in Public Offering of 4.150% Notes due 2027
Table 12: Eli Lilly Raises USD1 Billion in Public Offering of 4.2% Notes due 2029
List of Figures
Figure 1: Insulin Delivery Market, United Kingdom, Revenue ($m), USD Constant, 2018-2033
Figure 2: Insulin Pens Market, United Kingdom, Revenue ($m), USD Constant, 2018-2033
Figure 3: Insulin Pumps Market, United Kingdom, Revenue ($m), USD Constant, 2018-2033
Figure 4: Insulin Delivery Market, United Kingdom, Volume (Units), 2018-2033
Figure 5: Insulin Pens Market, United Kingdom, Volume (Units), 2018-2033
Figure 6: Insulin Pumps Market, United Kingdom, Volume (Units), 2018-2033
Figure 7: Insulin Delivery Market, United Kingdom, Company Share (%) 2023

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us